Additionally, results from another study demonstrated that the ORR, median PFS, and one-year OS rate of ICIs combined with chemotherapy for treatment-naive HER2-mutant NSCLC were 52%, 6 months and 88%, respectively (97). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.